Pacific Biosciences
PACB
98 hedge funds and large institutions have $430M invested in Pacific Biosciences in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 22 closing their positions.
121% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 19
53% more capital invested
Capital invested by funds: $281M → $430M (+$149M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0.06% less ownership
Funds ownership: 70.97% → 70.91% (-0.06%)
8% less funds holding
Funds holding: 107 → 98 (-9)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
87% less call options, than puts
Call options by funds: $260K | Put options by funds: $1.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$13.2M |
| 2 |
BlackRock
New York
|
+$7.37M |
| 3 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$4.3M |
| 4 |
SFM
Soros Fund Management
New York
|
+$2.88M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$4.8M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$4.42M |
| 3 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$3.06M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.14M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.76M |
PACB Hedge Fund Activity: Q3 2017 in Review
98 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2017, worth a combined $430M — up 53% from $281M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PACB and 14 opened new positions — a net loss of 8 holders — while 19 trimmed existing stakes and 42 added.
The largest buyer was Consonance Capital Management, adding an estimated $13.2M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $4.8M.
- 98 institutional investors held Pacific Biosciences (PACB) as of Q3 2017, down from 107 in Q2 2017.
- Funds reported $430M of Pacific Biosciences stock for Q3 2017, up 53% quarter-over-quarter.
- 14 funds opened new Pacific Biosciences positions in Q3 2017 and 22 closed out, a net change of -8 holders.
- The largest Pacific Biosciences buyer in Q3 2017 was Consonance Capital Management, an estimated $13.2M added.
- The largest Pacific Biosciences seller in Q3 2017 was Gilder Gagnon Howe & Co, an estimated $4.8M sold.
Based on aggregated 13F filings for Q3 2017.